Nektar Therapeutics (NKTR) Assets Average (2011 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Assets Average of $521.8 million for Q1 2026, up 86.34% year-over-year from $280.0 million in Q1 2025, and up 79.4% quarter-over-quarter from $290.9 million in Q4 2025.
Nektar Therapeutics (NKTR) Assets Average (2011 - 2026) Analysis & Trends
Nektar Therapeutics' Assets Average history runs 16 years deep, the most recent figure standing at $521.8 million for Q1 2026.
- In Q1 2026, Assets Average rose 86.34% year-over-year to $521.8 million; the TTM figure through Mar 2026 stood at $521.8 million (up 86.34% YoY), while the FY2025 annual figure was $292.1 million, down 16.76% from the prior year.
- Assets Average for Q1 2026 stood at $521.8 million, up from $290.9 million in the prior quarter.
- The five-year high for Assets Average was $1.1 billion in Q1 2022, with the low at $231.9 million in Q2 2025.
- The 5-year median for Assets Average is $420.1 million (2023), against an average of $506.5 million.
- The sharpest annual moves came in 2023 and 2026: Assets Average sank 44.01% in 2023, then surged 86.34% in 2026.
- Nektar Therapeutics' Assets Average stood at $745.8 million in 2022, then slumped by 43.67% to $420.1 million in 2023, then declined by 27.19% to $305.9 million in 2024, then slipped by 4.91% to $290.9 million in 2025, then soared by 79.4% to $521.8 million in 2026.
- Business Quant data shows NKTR's Assets Average at $521.8 million in Q1 2026, $290.9 million in Q4 2025, and $254.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | 521.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 521.84 Mn |
| Dec 31, 2025 | 290.88 Mn |
| Sep 30, 2025 | 254.44 Mn |
| Jun 30, 2025 | 231.89 Mn |
| Mar 31, 2025 | 280.05 Mn |
| Dec 31, 2024 | 305.91 Mn |
| Sep 30, 2024 | 325.65 Mn |
| Jun 30, 2024 | 369.67 Mn |
| Mar 31, 2024 | 397.02 Mn |
| Dec 31, 2023 | 420.14 Mn |
| Sep 30, 2023 | 468.26 Mn |
| Jun 30, 2023 | 528.01 Mn |
| Mar 31, 2023 | 636.17 Mn |
| Dec 31, 2022 | 745.80 Mn |
| Sep 30, 2022 | 821.50 Mn |
| Jun 30, 2022 | 943.05 Mn |
| Mar 31, 2022 | 1.07 Bn |
| Dec 31, 2021 | 1.20 Bn |
| Sep 30, 2021 | 1.32 Bn |
| Jun 30, 2021 | 1.41 Bn |